Current Report Filing (8-k)
21 June 2014 - 7:04AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event)
June 20, 2014; (June 20, 2014)
GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified
in Its Charter)
|
|
|
Delaware |
0-22179 |
58-2029543 |
(State or Other Jurisdiction of |
(Commission File Number) |
(IRS Employer Identification No.) |
Incorporation) |
|
|
|
|
5835 Peachtree Corners East, Suite D
Norcross, Georgia
(Address of Principal Executive Offices) |
30092
(Zip Code) |
Registrant's Telephone Number, Including Area
Code: (770) 242-8723
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ] |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
Item 5.07 Submission
of Matters to a Vote of Security Holders.
On
June 20, 2014, the Company held its annual meeting of stockholders in Atlanta, Georgia. As of the record date, April
24, 2014, there were 72,172,331 shares of Common Stock and 1,737 shares
of Series B preferred stock (common stock equivalent being 4,342,500 shares), voting on an as-converted basis
entitled to vote at the annual meeting. Represented at the meeting in person or by proxy were 60,121,438 votes representing
79 percent of the total shares of Common Stock entitled to vote at the meeting.
The
purpose of the meeting was to elect six directors, amend our Certificate of Incorporation to increase the number of
authorized shares of our common stock to a total of 195,000,000 shares, the non-binding, advisory approval of the compensation
of the Company’s named executive officers and to ratify the appointment of UHY, LLP as the Company’s independent auditors
for fiscal year 2014. The following table sets forth the results of the vote on the matters:
Proposal |
|
Votes |
Gene S. Cartwright, Ph.D. |
For |
33,358,541 |
|
Against |
30,459 |
|
Abstain |
26,706 |
|
Non Votes |
26,705,732 |
|
|
|
Ronald W. Hart, Ph.D. |
For |
20,940,509 |
|
Against |
12,185,269 |
|
Abstain |
289,928 |
|
Non Votes |
26,705,732 |
|
|
|
John E. Imhoff, M.D. |
For |
23,600,286 |
|
Against |
3,158,746 |
|
Abstain |
6,656,674 |
|
Non Votes |
26,705,732 |
|
|
|
Michael C. James |
For |
21,421,967 |
|
Against |
10,441,768 |
|
Abstain |
1,551,971 |
|
Non Votes |
26,705,732 |
|
|
|
Jonathan M. Niloff, M.D. |
For |
20,907,240 |
|
Against |
4,599,156 |
|
Abstain |
7,909,310 |
|
Non Votes |
26,705,732 |
|
|
|
Linda Rosenstock, M.D. |
For |
20,386,621 |
|
Against |
11,486,464 |
|
Abstain |
1,542,621 |
|
Non Votes |
26,705,732 |
|
|
|
Increase Shares |
For |
45,432,993 |
|
Against |
13,649,900 |
|
Abstain |
1,038,545 |
|
Non Votes |
0 |
|
|
|
Executive Compensation |
For |
22,928,596 |
|
Against |
2,716,137 |
|
Abstain |
1,383,423 |
|
Non Votes |
26,705,732 |
|
Uncast |
6,137,550 |
|
|
|
Auditors |
For |
56,749,182 |
|
Against |
1,811,753 |
|
Abstain |
1,560,503 |
|
Non Votes |
0 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GUIDED THERAPEUTICS, INC. |
|
|
|
|
|
|
By: |
/s/ Gene Cartwright |
|
|
|
Gene Cartwright |
|
|
|
Chief Executive Officer |
|
Date: June 20, 2014 |
|
|
|
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Jul 2023 to Jul 2024